Facebook Instagram Linkedin Twitter Website
Home Blog Page 139

Sun Life Financial launches first of its kind digital health network

By
IHR Magazine
-
0
Sun Life Financial launches first of its kind digital health network

Sun Life Assurance Company of Canada is making a significant commitment to help Canadians live healthier lives with the launch of Lumino Health – Canada’s premier network of health resources free to all Canadians through the website Luminohealth.ca. The innovative Lumino Health digital experience offers ratings, cost and other information to help Canadians find and select a health care resource that is the best fit for them within seconds.

“Lumino Health is a game changer and it’s about time a health network like this is available,” said Canadian Olympic hockey legend, Hayley Wickenheiser. “As an athlete, I’ve used my share of massage therapists, physiotherapists and dentists to help me be my best throughout my playing days, but now as a busy mom and medical student, Lumino Health makes it so much easier and quicker for me to find everything I need in one place.”

Here’s what Luminohealth.ca is bringing to Canadians:

  • Information on more than 150,000 health providers including dentists, massage therapists, chiropractors, physiotherapists, psychologists, vision care providers, naturopaths, acupuncturists and more from coast to coast;
  • More than six million ratings on these providers from Sun Life’s Clients who have used these services;
  • Ability to compare provider costs;
  • Helpful information like hours of operation, languages spoken and the ability to request an appointment online;
  • The latest apps, products and solutions from health innovators supported by reviews from a community of users; and
  • Insights from health industry experts on how to live a healthier life.

“What’s unique about Lumino Health is how quick and easy it is to find a health provider that fits your needs. In the past, if you moved, you would have relied on word of mouth or spent time researching to find a new set of health providers like dentists and physiotherapists. Now, you can use Luminohealth.ca to find the best matches for you in less than a minute,” says Chris Denys, Senior Vice-President, Possibilities, Sun Life Financial. “We want Lumino Health to be your one-stop-shop by providing credible information with an easy to use tool to make searching for what you need as simple as booking a hotel. By doing so, we hope it will empower Canadians to live healthier lives.”

Sun Life Assurance Company of Canada is a member of the Sun Life Financial group of companies.

 

More precaution than promotion for Canadian cannabis tourism

By
IHR Magazine
-
0
More precaution than promotion for Canadian cannabis tourism

TORONTO (Reuters) – Canadian cannabis tourism: Canada’s move to legalize recreational marijuana this week is unlikely to immediately trigger a flood of pot-fueled tourism, as tour operators and consumers are unsure about rules governing the brand new industry.

There are precedents for Canada to follow in California, Colorado and elsewhere. But observers noted that these U.S. states offering legal recreational marijuana could put a damper on Canada’s own pot travel aspirations: Why go all the way to Canada when you can smoke legally a couple of states away?

On Wednesday, Canada became the first major industrialized nation to legalize recreational marijuana, sparking huge demand. But those in the tourism industry are meeting legalization with more precaution than promotion.

“The tourist is really at the mercy of the drastically changing landscape,” said Neev Tapiero, who had a soft launch for his company, Canadian Kush Tours, months ago. “There are still other bugs to work out.”

The landscape changed on Wednesday with legalization. It will change again in six months when Ontario, Canada’s most populous province, allows for private storefronts, and again months after that if edible pot products become legal, he said.

Tapiero said he wishes government tourism agencies were more proactive in telling potential tourists what is and isn’t legal.

Denelle Balfour, a spokeswoman for Ontario’s Ministry of Tourism, Culture and Sport, said a general public awareness campaign directs people to an information site.

“We’ve only had a couple of calls” from would-be tourists asking about legal weed, said Gordon Orr, Chief Executive Officer of Tourism Windsor Essex. “One was, ‘Where do we get it?’”

Some tour operators are hesitant to highlight the fledgeling industry.

“We don’t use it as a promotion tool,” said Christian Wolters, Tour Radar’s managing director of North America. “If someone specifically is asking questions we indicate it is legal … but they have to be careful whenever they go back to their own country.”

Aaron Bowker, spokesman for U.S. Customs and Border Protection, had a tough message for the would-be visitors.

“I’ve been telling people for months now: If you do travel to Canada to recreationally use marijuana and you are a U.S. citizen, you are guaranteed entry to the United States. However … do not bring it back.”

On Wednesday, new posters went up at bus terminals across Canada targeted at a specific demographic: cannabis aficionados.

Bus tour operator Greyhound’s sign tells passengers where to pack the drug, where they can smoke it and, importantly, what to do with it if they’re crossing the border: Leave it behind.

But don’t expect American tourists to be too pot-savvy when they cross the border in search of Canada’s legal cannabis, said Ryan McConnell, senior vice president of Kantar Consulting, a firm that recently researched America’s “cannabis-curious.”

“You’re going to find some people thinking it’s a free-for-all, everything’s legal. That’s just not the case.”

Reporting by Anna Mehler Paperny; Editing by Bill Berkrot

Aphria sends cannabis oil to Argentina for study on epilepsy in children

By
IHR Magazine
-
0
Aphria sends cannabis oil to Argentina for study on epilepsy in children

Aphria delivers 1,500 bottles of Rideau oil to its subsidiary ABP to support the advancement of clinical medical cannabis research.

The Company also completes the first shipment of medical cannabis to Malta-based subsidiary ASG Pharma.

LEAMINGTON, ON, Oct. 15, 2018 /CNW/ – Aphria Inc. today announced that it has completed its first shipment of cannabis oil to its Argentina-based subsidiary ABP, S.A. (“ABP” or the “Argentinean Company“), a pharmaceutical import and distribution company. In accordance with a previously announced supply agreement, the Company delivered 1,500 bottles of Aphria’s renowned Rideau CBD oil, which were provided to Hospital de Pediatria Garrahan (“Hospital Garrahan” or the “Hospital“), a leading pediatric hospital located in Buenos Aires, for use in a clinical study focused on treating refractory epilepsy in children.

Aphria acquired ABP last month when the Company closed its acquisition of LATAM Holdings Inc. (“LATAM Holdings“), expanding the Company’s global footprint to include a leading presence in Latin America and the Caribbean. “Argentina will play a foundational role as Aphria cements its leadership in medical cannabis throughout the region,” said Vic Neufeld, Chief Executive Officer of Aphria. “Aphria and ABP, in close partnership with the Argentinean government, continue to advance opportunities for medical cannabis in the country, including the potential for in-country cultivation. We are also proud to support the critical and necessary research being undertaken by Hospital Garrahan on the treatment of refractory epilepsy in children with our Rideau CBD oil.”

As a well-established and successful pharmaceutical import and distribution company, ABP was granted the first permit issued by the Argentina Ministry of Health for the import of pharmaceutical-grade medical cannabis. The Argentinean Company has been forging a reputation as a champion for the research and clinical study of medical cannabis, including through its partnership with the Hospital, one of the most recognized and credible medical institutions in South America.

The clinical study, which involves 100 patients and will be conducted over 2.5 years, will be one of the foundational global scientific and medical studies of its kind focused on treating refractory epilepsy in children. Medical researchers will conduct a pharmacokinetics study of the Rideau product, which will help optimize the ideal dosage in future patients. Top neurologists and pediatric specialists from around the country will participate and, with the support of ABP and Aphria, will receive training and support to be able to train and educate a network of doctors throughout Argentina.

Aphria completes the first shipment of medical cannabis to ASG Pharma

The Company also announced it has completed its first shipment of cannabis oil to its Malta-based subsidiary ASG Pharma Ltd. (“ASG“). The majority-owned subsidiary received the first import certificate for medical cannabis issued by the Government of Malta’s Ministry of Health and will use this first delivery of Aphria’s renowned Rideau CBD oil to perform analytical testing and research.

“This marks another important milestone as we continue to execute on our strategic expansion plans in Europe and around the world,” added Neufeld. “Our EU-GMP certified lab in Malta will play an important role for the Company in accessing cannabis markets across the continent, and it will stand as a leading European centre for the research and testing of medical cannabis and derivative products.”

ASG’s facilities, which are undergoing a multi-million-euro upgrade of its processing and manufacturing capabilities, will serve as Aphria’s hub for importing cannabis resin and dried flower for processing, packaging and distribution of EU-GMP certified cannabis products throughout large parts of Europe

John Craig joins LeBeau Excel Ltd.

By
IHR Magazine
-
0
John Craig joins LeBeau Excel Ltd.

For immediate release: John Craig is joining LeBeau Excel Sales & Marketing the as new Director of Sales for English Canada on Nov 5 th 2018.
Hailing from Burlington Ontario, John and his wife, Gail, have 2 kids who are at the post-secondary and adult phases of life.

John has spent the last 9 years with VEGA holding several key sales leadership positions and helped guide the team through many changes including their meteoric rise through to the corporate sale and eventual settling in as a division of Danone. John has also managed many key accounts over his various tenures including Costco, GNC and others. John holds a BA from Western University and spent 5 years with Iovate Health Sciences as the Director of Sales previous to joining VEGA.

All of our outside salespeople, excluding Quebec, will align under this newly created role as John works closely with Deb Ritcey & Eamonn McKay to drive improvements through our team. John will also manage Shoppers Drug Mart and collaborate on LCL generally.

John brings a wealth of organizational experience and managing sales team as we push forward with our mandate to make LeBeau Excel more efficient, transparent and easy to do business with. We look forward to his contributions and collaborations as a leader in our business.

You can reach John at john@lebeauadvance.com or 647-283-6277.

Albertsons Grocer Starts E-commerce Pilot Project

By
IHR Magazine
-
0
Albertsons Grocer Starts E-commerce Pilot Project

Albertsons Cos. has entered a technology partnership to begin building a back-end infrastructure for e-commerce.

The Boise, Idaho-based grocer recently said that it has teamed up with e-grocery automation startup Takeoff Technologies to create a pilot project to create a hyperlocal micro-fulfilment centre with an existing store. Albertsons called the partnership “a major step in our commitment to being a customer-centric player in the digital food and wellness ecosystem.

The effort comes as retailers are looking to data to help inform their buying decisions. It also comes as grocers increasingly focus on the local or upstart brands that shoppers are now wanting.

Takeoff’s artificial intelligence-enabled robots can collect items for online grocery orders in minutes, at a fraction of the speed and cost of manual-picking processes. With the move, Albertsons said it’s the first national grocer to implement an automated e-commerce fulfilment solution for customers.

“If you’re a small player with a very good product or a big consumer packaged goods company with a small unit, you will struggle to get the attention of some of our larger banners,” said Narayan Iyengar, senior vice president of digital marketing and e-commerce at Albertsons.

“Investing in e-commerce directly benefits our customers, and anything that we can do to simplify their grocery shopping experience to save valuable time is a win,” Iyengar said in a statement. “While our partnership with Takeoff Technologies will streamline e-commerce fulfilment and improve our efficiencies, we’re excited that Takeoff’s AI solution will make it even easier for customers to get their groceries how and when they want.”

How will it work?

Albertsons customers will place their grocery orders online or via a mobile, and the orders are then routed to an automated system. Takeoff’s facility then takes over the fulfilment process. The AI-enabled robots and a system of totes and conveyors deliver the items to an Albertsons’ employee, who prepares the orders for customers.

The companies noted that the system slashes the amount of time for individual customer orders to be processed. And the automated warehouse is replenished daily, just as supermarket store shelves are stocked regularly, they said.

“Our e-grocery automation is a turnkey solution that uses artificial intelligence to unlock ultimate convenience for shoppers without the need of charging fees or a price premium,” said Max Pedro, co-founder and president of Waltham, Mass.-based Takeoff in a statement.

The retailer, which has nearly 2,300 stores in 35 states, noted that Takeoff’s model leverages the existing supply chain and store footprint and is flexible in picking various types of products.

 

Aura Closes $400,000 Convertible Debenture Offering

By
IHR Magazine
-
0
Aura Closes $400

 Aura Health Inc. is very pleased to announce that it has closed a non-brokered private placement offering (the “Offering”) on October 26th, 2018 (“Closing Date”) of unsecured convertible debentures bearing interest at a rate of 10% per annum, payable quarterly in arrears (each a “Debenture”, and together the “Debentures”), for gross proceeds of CAD$400,000. The proceeds of the Offering will be used by the Company for general working capital requirements and general corporate purposes.

Each Debenture is convertible at the conversion price of $0.365 (the “Conversion Price”) into units (the “Units”) consisting of one common share in the capital of the Company (each a “Common Share”, and together the “Common Shares”) and one-half of one common share purchase warrant (the “Warrants”) exercisable at the conversion price of $0.50 per Common Share for a period of 24 months from the date of issuance.

The Debentures are exercisable until October 26, 2020, or until such time that the Common Shares of the Company trade on the Canadian Stock Exchange for a period of 20 consecutive trading days at a price of $0.60, upon which the Common Shares will automatically convert into Units at the Conversion Price.

The Debentures and any securities which may subsequently be issued in relation thereto are subject to a four month and one day hold period.

Daniel Cohen, Chief Executive Officer of the Company participated in the Offering, subscribing to a $200,000 Debenture. Such participation is considered a related party transaction within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The related party transaction is exempt from minority approval, information circular, and formal valuation requirements pursuant to the exemptions contained in Sections 5.7(a) and 5.5(a) of MI 61-101, as neither the fair market value of the gross securities issued under the Offering nor the consideration paid by Daniel Cohen exceed 25% of the Company’s market capitalization.—GLOBE NEWSWIRE

About Aura Health Inc.

Aura is building an international network of vertically-integrated cannabis assets. The company has LOIs in place to acquire the majority of two Israeli assets: HolyCanna, a cultivation and nursery license holder, and CannabiSendak, the builder of a network of high-profile dispensaries. Aura also owns a 30% interest in four medical marijuana clinics in the U.S. Sun Belt, with an option to increase its interest in three of the clinics to 51%.

Weed Advisor first to offer a legal, retail credit card platform for cannabis products in Canada

By
IHR Magazine
-
0
Weed Advisor first to offer a legal

– National, independent survey shows consumer acceptance toward online and dispensary purchases –

Weed Advisor, a cannabis platform service that supplies the latest access to products, information, business solutions and consumer insights to the cannabis industry, has launched a first-to-market legal retail credit card payment processing platform for hundreds of products and counting, available at weedadvisor.com.

While other online cannabis-focused sites offer sales through e-transfers, C.O.D. transactions and third-party channels such as PayPal, as of Canadian cannabis legalization today, Weed Advisor will offer the same type of PCI compliant transactions utilized to purchase music, furniture, computer hardware & software, food & beverage, and clothing, to name a few industries – virtually everything people have come to grow accustomed to when buying online.

“Consumers look for convenience, insurance and a sense of overall security when shopping online – regardless of the product or service they plan to purchase,” says Gregory Luciani, President and CEO of Weed Advisor. “Legalization doesn’t always equate to a comfort level of use, which is exactly the problem we are addressing, as industry-wide understanding continues to evolve. We’re providing a trusted source for online purchasing that offers significant options and substance.”

This allows Weed Advisor to offer direct consumer benefits, as well as a quick and simple sales channel for retailers that may or may not have a bricks-and-mortar presence. Once a license is legally produced and accepted by Weed Advisor, it is just a matter of hours that products are filtered – as another legal step in the process – at the Weed Advisor site and ready for sale.

“This is a new business frontier in Canada, so we were careful in our approach to building block partnerships,” says Danny Gurizzan, Chief Executive Officer at PSP Card Services. “Weed Advisor’s offerings, original approach and ongoing commitment to customer service align with our own business model, which is why we chose to work with their team right out of the gate.”

Supported through multi-million dollars of investment through private equity firms, the initial rollout of the credit card payment processing platform will immediately provide select offerings upon legalization, while products will continue to be added to the in-stock listings going forward.

An early adopter and partner of the Weed Advisor platform is Snowy River International, a world-renowned cyber security firm based out of Alberta that critically ensures safe sharing of information and cyber integrity.

“Snowy River International prides itself on our work behind safety of web-based transactions,” says Wayne Ronhaar, CEO of Snowy River International. “Adding our expertise to the Weed Advisor experience in this evolving cannabis market assures we are resilient and responsive to customer needs.”

 

Two other timely initiatives that complement the new payment processing platform include:

  • In-house Weed Advisor financing options for businesses interested in the company’s proprietary B2B and B2C suite of solutions; and
  • Soon-to-be-offered Weed Advisor credit cards, offering all the benefits and security of your typical credit card.

 

INDEPENDENT ONLINE STUDY BRINGS CONSUMER OPINIONS TO LIGHT AS LEGALIZATION APPROACHES

Along with its payment platform initiative, Weed Advisor also conducted an independent national survey through its extensive database to identify and explore trends within the Canadian consumer marketplace.

 

Three key findings reveal:

  • Despite potential for lack of brand familiarity with new, wide ranging options, 63 per cent of respondents say this won’t keep them from purchasing through dispensaries and online sites, citing the upside of safety, stability, ingredient information, and a chance to try something new.
  • Legalization will open doors to friends trying/re-connecting with cannabis, according to 60 per cent of those surveyed, based on the ideas surrounding increased access and acceptance.
  • Due to long-term stereotyping and decades of negativity around cannabis use, 85 per cent believe a certain stigma will remain even after legalization.

 

Other survey results include:

  • 25 per cent plan to purchase cannabis using all three main channels – their black market source, dispensaries and online
  • “Only through web-based sales” shows the most individual promise for sales at 27 per cent, with “only at dispensaries” at 26 per cent and “only via black market” at 23 per cent
  • 62 per cent are somewhat informed about the new street laws, but feel it’s too early to truly tell what will take place regarding enforcement of legal specifics

“Clearly, Canadians have strong opinions on legalization and their approach to the changing environment around cannabis,” says Krishnan Wignarajah, Chief Operating & Information Officer at Weed Advisor. “It’s encouraging to see definitive positions taken and especially motivating for the industry since there is strong support for dispensaries and online purchasing. It speaks to Canada’s open-minded approach to this ground-breaking position on acceptance.”-CNW

METRO INC. – Dividend Notice

By
IHR Magazine
-
0

METRO INC. declares a quarterly dividend of $0.18 per common share, payable on November 13, 2018 to shareholders of record as at October 26, 2018. This quarterly dividend represents an increase of 10.8% over the same quarter last year.

About METRO INC.
With annual sales of approximately $16 billion, METRO INC. is a leader in food and pharmaceutical distribution in Québec, Ontario and Eastern Canada, where it operates or is the franchisor of a network of more than 600 food stores under several banners, including Metro, Metro Plus, Super C and Food Basics, as well as close to 700 drugstores primarily under the Jean Coutu, Brunet, Metro Pharmacy and Drug Basics banners, providing employment to 85,000 people. For more details, visit corpo.metro.ca.-CNW

(gavinbros.com)

Why Medical Marijuana Has Healthcare Companies Scrambling to Invest in the $10 Billion Industry

By
IHR Magazine
-
0
Why Medical Marijuana Has Healthcare Companies Scrambling to Invest in the $10 Billion Industry

Frost & Sullivan will host an interactive briefing discussing the medical marijuana market revenue trends and challenges.

Frost & Sullivan, the growth partnership company, announced today that it will host a live, complimentary Growth Innovation Leadership (GIL) briefing titled, “Medical Marijuana Market Trends – Future Clinical Role of Medical Marijuana & CBD,” on Tuesday, October 30, 2018, from 1:00 to 2:00 PM Pacific Time. The webinar will offer expert insight from Nitin Naik, Global Vice President, Life Sciences, Barbara Gilmore, Senior Consultant, Life Sciences, both at Frost & Sullivan, and Dr. Joseph C. Maroon, Clinical Professor and Vice Chairman, at the University of Pittsburgh.

For more information and to register for the webinar, please visit http://frost.ly/2t3.

Medical cannabis use is driving industry revenues into the billions. Investments by pharmaceutical and Big Tobacco companies in the development of cannabis and CBD-based products and devices, along with healthcare-conscious consumers having access to these products, are spurring growth. Physicians, aware of increasingly widespread medical marijuana legalization, are interested in understanding the potential of these treatments. In the US states where cannabis is approved, the use of prescription drugs, including the use of opioids, has decreased.

“The use of medical marijuana is sparking keen interest not only with investors, but also doctors and patients. All but four states in the US have legalized either medical marijuana or CBD use. There are over 770 clinical trials underway studying the use of medical cannabis in various diseases and another more than 500 trials studying the use of CBD,” noted Gilmore. “With all of these studies underway, it is interesting to note that states that have legalized marijuana for recreational use have seen a steady decrease in the number of recorded patient prescriptions. This is a trend that will be studied going forward as physicians learn more about the medical marijuana efficacy as it related to the diseases it is successfully treating.”

The informative webinar will cover key insights:

  • Learn about a variety of medical marijuana science and clinical uses/applications (patient experiences);
  • Discover health-related applications of medical marijuana based on interactions with the endocannabinoid system; and
  • Explore the latest clinical research in cancer, neurological, psychological, metabolic and pain disorders using medical marijuana.

The event will also be recorded and available for on-demand viewing at http://frost.ly/1ti.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion. -CNW

 

Organigram Announces Definitive Agreement to Acquire 25% of alpha-cannabis® Pharma GmbH

By
IHR Magazine
-
0
Organigram Announces Definitive Agreement to Acquire 25% of alpha-cannabis® Pharma GmbH

Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQX: OGRMF), a leading licensed producer of medical marijuana, is pleased to announce that it has, through its wholly-owned subsidiary 10870277 Canada Inc. (the “Purchaser” or “OGI”), executed an investment agreement dated as of October 10, 2018 with alpha-cannabis® Pharma GmbH (“Alpha-Cannabis Germany” or “ACG”) pursuant to which the Purchaser will acquire 8,333 common shares of ACG, representing a 25% stake in the capital of ACG, for aggregate proceeds of €1,625,000. The closing is subject to certain formalities under German law largely of an administrative nature.

As part of the investment and effective upon the closing of the investment, OGI’s wholly-owned subsidiary, Organigram Inc. will enter into two supply agreements with ACG: one for the supply of cannabidiol isolate from ACG to Organigram Inc., and the other for the supply of dried cannabis flower from Organigram Inc. to ACG. In addition, ACG and Organigram Inc. will enter into an agreement pursuant to which the companies will jointly evaluate and bid on certain licenses to supply medical cannabis to the German market.

In addition, upon ACG achieving certain milestones, the Purchaser will pay ACG additional consideration of €875,000 payable in common shares of OGI to be valued in accordance with a volume-weighted average price formula described in the investment agreement. The issuance of the OGI shares is subject to compliance with TSXV corporate policies.

Alpha-Cannabis’ Managing Directors Alexander Klomsdorff and newly appointed Dr. Volker Christoffel are pleased that the agreement with Organigram has now been formally finalized. ACG has been preparing the development and production of further cannabis based products for the swiftly growing German and European Markets following their recent product launch of “Cannabidiol alpha DAC”. “We look forward to a strong and fruitful partnership with our Canadian partners as we see significant potential in jointly materializing the medicinal benefits of Cannabinoids” ACG’s Managing Directors stated.

“As we continue to build the framework of our international medical business, finding the right partners in the right markets has been a priority for our company,” stated Greg Engel, CEO at Organigram. “This relationship is a perfect example of two companies coming together towards a common goal, and we’re very excited to build our business in Germany through our partners at alpha-cannabis® Pharma GmbH”

About alpha-cannabis® Pharma GmbH

Established in 2016, Alpha-Cannabis Germany is strategically positioned to serve the German medical cannabis market which is quickly becoming one of the largest markets for medical cannabis in the world. Additionally, the German market is positioned as a potential gateway to supplying other European markets. With team of highly experienced and reputable specialists from the pharmaceutical industry with scientific and business backgrounds, ACG is focused on the development, production and marketing of Cannabis based APIs (Active Pharmaceutical Ingredients) and pharmaceuticals. ACG’s activities cover the spectrum of cannabinoids. The company enjoys a strong network of professional partners throughout Germany and its recently announced launch of a CBD kit will be available in over 20,000 pharmacies throughout Germany, Austria and Switzerland.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Organigram is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company’s global footprint. In anticipation of the legal adult use recreational cannabis market in Canada, Organigram has developed a portfolio of brands including The Edison Cannabis Company, Ankr Organics, Trailblazer and Trailer Park Buds. Organigram’s primary facility is located in Moncton, New Brunswick and the Company is regulated by the Health Canada.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking information which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors – including the interpretation of the Cannabis Act and promotional activities, the availability of funds, the results of financing efforts, crop yields – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information on OGI, please visit: www.Organigram.ca . -CNW

1...138139140...389Page 139 of 389

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

© 2026 IHR Magazine | Canada's Natural Health Industry Authority | Le guide de l’industrie canadienne de la santé naturelle